



# The Potency of Piperine as Magnesium Bioenhancer in Mice Lung

Tri Yuliani<sup>1</sup>(✉), Hikmat Hikmat<sup>2</sup>, Indah D. Dewijanti<sup>1</sup>, Rizna T. Dewi<sup>1</sup>,  
Marissa Angelina<sup>1</sup>, Sofa Fajriah<sup>1</sup>, and Instiaty Instiaty<sup>3</sup>

<sup>1</sup> Research Center for Pharmaceutical Ingredients and Traditional Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN) Kawasan PUSPIPTEK Serpong, Tangerang Selatan, Banten 15314, Indonesia  
[tri.yuliani@brin.go.id](mailto:tri.yuliani@brin.go.id)

<sup>2</sup> Research Center for Chemistry, National Research and Innovation Agency (BRIN) Kawasan PUSPIPTEK Serpong, Tangerang Selatan, Banten 15314, Indonesia

<sup>3</sup> Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia

**Abstract.** Magnesium (Mg) deficiency is found in many disease conditions ranging from infectious diseases to degenerative diseases. In COVID-19, magnesium deficiency is associated with susceptibility to infection and the development of severe infections. In this disease, magnesium has been suggested to play a role in the regulation of the immune system, inflammation, and bronchodilatation. Unfortunately, despite its cheap price and abundant availability in nature, magnesium deficiency is difficult to treat. Deficiency persists even after supplementation. Lack of compliance due to side effects at high doses is also another problem. This study aims to investigate the effect of piperine as a magnesium bioenhancer by measuring the bioavailability of magnesium in the lungs of healthy mice using graphite furnace atomic absorption spectrometry (GF-AAS). In addition, two different administrations were compared, ie. Repeated dose oral administrations (5 times/5 days) and single dose intraperitoneal administrations in which each of them consist of 3 testing substances, ie. Magnesium only ( $\text{MgSO}_4$  100 mg/kg), piperine only (10 mg/kg), and the combination of magnesium and piperine. One group receives no treatment and serves as a control. The results showed that piperine could increase the uptake of magnesium in the lungs. Surprisingly, this effect is independent of magnesium intake because co-administration of magnesium reduced the uptake of magnesium in the lungs. Of note, single intra peritoneal administration shows a much more prominent effect than repeated doses of oral administration. We suggest piperine could be used as a magnesium bioenhancer in the lung. Future studies using different animal models seem warranted.

**Keywords:** piperine · magnesium · bioenhancer · in vivo · lung

## 1 Introduction

Aging and diabetes are two factors that cause severe attacks in COVID-19 patients. Interestingly, both of these conditions are associated with magnesium (Mg) deficiency. Magnesium is the most abundant intracellular cation after potassium and is involved in > 600 enzymatic reactions in the body, including those that contribute to immune and inflammatory responses in COVID-19 patients [1]. The function of magnesium in the immune response is as a cofactor for the synthesis of immunoglobulins and cofactors of other processes that play a role in the function of T cells and B cells. Regulation of magnesium in immune cells involves several magnesium transport systems [1, 2].

For the treatment of respiratory disease, magnesium sulfate has been widely used in acute severe asthma. As a natural calcium antagonist, the mechanism of action of magnesium in this disease involves inhibition of airway smooth muscle contraction, dilatation of the pulmonary arteries, and reduction of pulmonary artery resistance leading to alleviation of hypoxia [3].

Despite its abundant availability in nature, unfortunately, magnesium deficiency in patients is difficult to treat. This condition occurs because an increase in magnesium intake can also be followed by an increase in its elimination [1]. Therefore, it is necessary to find a way to increase the bioavailability of magnesium, preferably without increasing its side effects, for example, by administering magnesium together with piperine as a bioenhancer.

Piperine is an alkaloid compound that is found in many Piper species plants. These plants have been used for spices and traditional medicine, eg. to treat infections. In the modern world, piperine has been known as a bioenhancer, which is a compound that can increase the bioavailability of several drug compounds and nutrients. There are also commercial preparations of piperine as a bioenhancer (Bioperine®; standardized extract with 95% piperine).

Some of the mechanism of piperine as a bioenhancer involves: 1) efflux-pump inhibition [4]; 2) inhibition of metabolizing enzymes; 3) the thermogenic properties of piperine in the intestine; 4) increase of blood supply; 5) decrease of hydrochloric acid secretion; 6) increase of active and passive nutrient transport; 7) inhibition of drug elimination; and 8) increase of free drug levels by replacing drug binding with plasma proteins [5].

Apart from being a bioenhancer, piperine also has an anti-infective therapeutic effect *in vivo* at the same dose as a bioenhancer (5–20 mg/kg) [6–9]. Piperine also has activity as an immunomodulator [10]. The nature of piperine as an efflux pump inhibitor indicates the potential of piperine to overcome antibiotic resistance caused by the overactivity of the efflux pump [11].

The benefits of piperine in respiratory disorders have been demonstrated in clinical and pre-clinical trials. In clinical trials, a new formulation of an anti-tuberculosis drug with piperine (Risorine®) has given promising results in the phase III clinical trial [12]. In this clinical trial, piperine 10 mg/kg can reduce rifampicin dose and reduce toxicity during therapy. In pre-clinical trials, piperine inhibited Th-2-mediated cytokine release, eosinophil infiltration, and airway hyper-responsiveness [13].

Although the effectiveness of piperine as a bioenhancer of several organic compounds is known pre-clinically and clinically, the effectiveness of piperine as a bioenhancer of essential minerals, especially magnesium, is still scarce. There is only a report on iron, zinc, and calcium in an ex-vivo study [14]. Similarly, its effect was only reported on iron bioavailability in a clinical study using athletes as the subject [15].

Two ongoing clinical trials are investigating the effects of magnesium and piperine but as separate testing substances. First, they investigate the effects of piperine as a curcumin bioenhancer for the treatment of COVID-19 patients [16], and second, they investigate the combination of magnesium with standard therapy in moderate and severe COVID-19 patients [3].

Taken together, targeting magnesium as a preventive and curative strategy in respiratory disorders seems warranted [17]. Using piperine, this study aims to investigate magnesium bioavailability in lung mice.

## 2 Material and Methods

### 2.1 Animals and Treatments

28 male Balb/C mice (The National Agency of Drug and Food Control/ BPOM) were grouped into 7 groups of 4 each, marked with permanent markers, and given food and drink ad libitum in standard mice cages. After acclimatization for 1 week, mice were treated orally (p.o) or intraperitoneally (i.p) as follows:

group without treatment, the piperine group 10 mg/kg i.p, piperine group 10 mg/kg p.o 5 days, group MgSO<sub>4</sub> 100 mg/kg i.v, group MgSO<sub>4</sub> 100 mg/kg p.o. for 5 days, piperine group dose 10 mg/kg + MgSO<sub>4</sub> 100 mg/kg i.v, piperine group dose 10 mg/kg + MgSO<sub>4</sub> 100 mg/kg p.o 5 days. Three hours after administration of the last test compound, mice were decapitated with neck dislocation. Lung samples were quickly collected and stored at - 80 °C until analysis. The protocol of this study has been approved by LIPI research ethics committee No. 43/klirens/VII/2021.

## 2.2 Magnesium Analysis

For magnesium analysis with Graphite Furnace Atomic Absorption Spectrophotometer (GF-AAS), lung samples were prepared by wet digestion in concentrated nitric acid (0.2 g samples in 3.6 mL nitric acid) at 120 °C for 30 min using a heat block (ECO COD Thermoreactors) in polypropylene tubes.

## 2.3 Materials

All materials were obtained from Sigma unless otherwise noted. Piperine was isolated from white pepper (*Piper nigrum*).  $\text{MgSO}_4$  (>90%).

## 2.4 Statistical Analysis

Data are presented as means  $\pm$  S.E.M of N experiments. GraphPad Prism® Version 5.03 was used for presenting the data and performing statistical analysis. A significance level of 0.05 was chosen for the tests. Analysis of variance (ANOVA) was used for comparing means of more than two groups followed by Tukey's Multiple Comparison Test. The unpaired-T test was used to compare the means between the 2 groups.


## 3 Results

Our data showed that administration of magnesium alone, both single dose intraperitoneally and multiple doses orally (5 $\times$ ), could not increase magnesium uptake in the lungs (5960 ng/g vs 5616 ng/g vs 5741 ng/g;  $p > 0.05$ ) (Fig. 1a).

Interestingly, a single administration of piperine could increase magnesium uptake in the lungs significantly when given intraperitoneally compared to control (5950 ng/g vs 7672 ng/g;  $p < 0.05$ ). However, this effect was reduced when magnesium was given with piperine concomitantly although a slight increase in magnesium uptake was still observed compared to control (5950 ng/g vs 6254 ng/g;  $p > 0.05$ ) (Fig. 1b.).

Next, we change the dosing regimen to multiple dose oral administration. Similar patterns were observed between multiple oral administration and intraperitoneal administration. Piperine alone showed the highest magnesium uptake (6815 ng/g;  $p > 0.05$ ). However, this effect was almost abolished to a similar value as control when magnesium was given with piperine concomitantly (5950 ng/g vs 5962 ng/g;  $p > 0.05$ ) (Fig. 1c.).

Regarding the dosing regimen of piperine, a single intraperitoneal injection shows a better effect than a repeated dose (5 $\times$ ) of oral administration. However, both regimen is not statistically significant (7672 ng/g vs 6815 ng/g;  $p > 0.05$ ) (Fig. 1d.).



**Fig. 1.** **a.** Magnesium level in lung sample after oral (po) and intraperitoneal administration (ip) compared to control. Magnesium administration could not increase magnesium uptake in the lungs. Data were analyzed by one-way ANOVA followed by Tukey's Multiple Comparison Test ( $p > 0.05$  compared to control). **b.** Magnesium level in lung sample. A single dose of piperine could significantly increase magnesium uptake in the lungs when given intraperitoneally. Data were analyzed by one-way ANOVA followed by Tukey's Multiple Comparison Test ( $*p < 0.05$  compared to control). **c.** Magnesium level in lung sample. Multiple doses of piperine slightly increased magnesium uptake in the lungs when given orally. Data were analyzed by one-way ANOVA followed by Tukey's Multiple Comparison Test ( $p > 0.05$  compared to control). **d.** Magnesium level in lung sample. The different dosing regimen of piperine shows no statistical difference between intraperitoneal and oral administration). Data were analyzed by unpaired t-test ( $p > 0.05$ ).

## 4 Discussion

Recent studies show that magnesium plays a pivotal role in the severity of COVID-19. This is because some of the risk factors that lead to severe COVID-19, eg diabetes mellitus and cardiovascular disease, were found to be related to magnesium deficiency [18, 19].

There are several ways to alleviate magnesium deficiency, one of them is the use of bioenhancers. One characteristic of bioenhancers is having a sharply strong taste or smell. In this study, we choose piperine. Besides having anti-infective properties, piperine is easily isolated. Therefore, it will be affordable in the future market. Of note, the activity of piperine as magnesium bioenhancer is rarely reported.

Our study showed that magnesium supplementation alone cannot increase magnesium uptake in the lung. This condition is possibly caused by the increase in its clearance. Surprisingly, piperine could increase the uptake of magnesium in the lungs. As predicted, this effect is independent of magnesium intake because co-administration of magnesium reduced the uptake of magnesium in the lungs. This condition is possibly caused by, again, its clearance.

Regarding the dosing regimen, we suggest that the route of administration, instead of total dosing, contributes more to the activity of piperine. The lower activity of piperine as magnesium bioenhancer, when given orally compared to intraperitoneally, is possibly caused by lower piperine blood level. Bhat [20] reported higher liver bioavailability of piperine when given intra peritoneally compared to orally.

Finally, even though oral administration of piperine showed lower magnesium bioenhancer activity, oral administration for future study seems warranted because the differences between oral and intraperitoneal are not statistically different. Of note, oral administration seems more applicable to clinical application.

The limitation of our study is that we use a normal animal. This is however not entirely incorrect because the purpose of this study is to show a clear effect between testing compounds (magnesium alone, with piperine, or piperine alone) and different dosing regimens (single intraperitoneal injection vs multiple doses oral administration). It will be more difficult to study such an effect if we directly use the animal model because so many variables will be involved. In other words, this study serves as a foundation for future studies using animal models.

The use of animal models of diseases is inevitable to study the mechanism of piperine in magnesium regulation because tissue biopsy in the patient is often unethical. In addition, animal models are needed to see the phenotype of this mechanism. Therefore, future studies using different animal models seem warranted.

**Acknowledgment.** The study was supported by internal fund PN IPT LIPI 2021.

## References

1. Wallace TC. Combating COVID-19 and Building Immune Resilience: A potential role for magnesium nutrition? *J Am Coll Nutr.* 2020, 39(8):685-693.

2. Dominguez LJ, Veronese N, Guerrero-Romero F, Barbagallo M. Magnesium in infectious diseases in older people. *Nutrients*. 2021;13(1):180.
3. Pourdowlat G, Mousavinasab SR, Farzanegan B, Kashefzadeh A, Meybodi ZA, Jafarzadeh M, Baniyasi S. Evaluation of the efficacy and safety of inhaled magnesium sulphate in combination with standard treatment in patients with moderate or severe COVID-19: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021;22(1):60.
4. Hegeto LA, Caleffi-Ferracioli KR, Perez de Souza J, Almeida AL, Nakamura de Vasconcelos SS, Barros ILE, Canezin PH, Campanerut-Sá PAZ, Scodro RBL, Siqueira VLD, Teixeira JJV, Cardoso RF. Promising antituberculosis activity of piperine combined with antimicrobials: A systematic review. *Microb Drug Resist*. 2019;25(1):120–126.
5. Dubey RK, Leeners B, Imthurn B, Merki-Feld GS, Rosselli M. Piperine decreases binding of drugs to human plasma and increases uptake by brain microvascular endothelial cells. *Phytother Res*. 2017;31(12):1868–1874.
6. Veerareddy PR, Vobalaboina V, Nahid A. Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. *Pharmazie*. 2004;59(3):194–7.
7. Toyoda T, Shi L, Takasu S, Cho YM, Kiriyama Y, Nishikawa A, Ogawa K, Tatematsu M, Tsukamoto T. Anti-inflammatory effects of capsaicin and piperine on helicobacter pylori-induced chronic gastritis in mongolian gerbils. *Helicobacter*. 2016;21(2):131–42.
8. Zhai WJ, Zhang ZB, Xu NN, Guo YF, Qiu C, Li CY, Deng GZ, Guo MY. Piperine plays an anti-inflammatory role in *Staphylococcus aureus* endometritis by inhibiting activation of NF- $\kappa$ B and MAPK pathways in mice. *Evid Based Complement Alternat Med*. 2016;2016:8597208.
9. Pan H, Xu LH, Huang MY, Zha QB, Zhao GX, Hou XF, Shi ZJ, Lin QR, Ouyang DY, He XH. Piperine metabolically regulates peritoneal resident macrophages to potentiate their functions against bacterial infection. *Oncotarget*. 2015;6(32):32468–83.
10. Liang YD, Bai WJ, Li CG, Xu LH, Wei HX, Pan H, He XH, Ouyang DY. Piperine suppresses pyroptosis and interleukin-1 $\beta$  release upon ATP triggering and bacterial infection. *Front Pharmacol*. 2016;7:390.
11. Zhang Y, Zhang J, Cui P, Zhang Y, Zhang W. Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008, and Rv1667c involved in pyrazinamide resistance in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother*. 2017;61(8):e00940–17.
12. Patel N, Jagannath K, Vora A, Patel M, Patel A. A randomized, controlled, phase III clinical trial to evaluate the efficacy and tolerability of risorine with conventional rifampicin in the treatment of newly diagnosed pulmonary tuberculosis patients. *J Assoc Physicians India*. 2017;65(9):48–54.
13. Kim, Seung-Hyung, and Young-Cheol Lee. Piperine inhibits eosinophil infiltration and airway hyperresponsiveness by suppressing T cell activity and Th2 cytokine production in the ovalbumin-induced asthma model. *J Pharm and Pharmacol*. 2009. 61(3): 353–59.
14. Prakash UN, Srinivasan K. Enhanced intestinal uptake of iron, zinc and calcium in rats fed pungent spice principles--piperine, capsaicin and ginger (*Zingiber officinale*). *J Trace Elem Med Biol*. 2013;27(3):184–90.
15. Fernández-Lázaro D, Mielgo-Ayuso J, Córdova Martínez A, Seco-Calvo J. Iron and physical activity: Bioavailability enhancers, properties of black pepper (Bioferine®) and potential applications. *Nutrients*. 2020;12(6):1886.
16. Miryan M, Bagherniya M, Sahebkar A, Soleimani D, Rouhani MH, Iraj B, Askari G. Effects of curcumin-piperine co-supplementation on clinical signs, duration, severity, and inflammatory factors in patients with COVID-19: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020;21(1):1027.
17. Tang CF, Ding H, Jiao RQ, Wu XX, Kong LD. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. *Eur J Pharmacol*. 2020;5,886:173546.

18. van Kempen TATG, Deixler E. SARS-CoV-2: influence of phosphate and magnesium, moderated by vitamin D, on energy (ATP) metabolism and on severity of COVID-19. *Am J Physiol Endocrinol Metab.* 2021;320(1):E2-E6.
19. Zeng HL, Yang Q, Yuan P, Wang X, Cheng L. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19. *FASEB J.* 2021;35(3):e21392.
20. Bhat BG, Chandrasekhara N. Studies on the metabolism of piperine: absorption, tissue distribution and excretion of urinary conjugates in rats. *Toxicology.* 1986;40(1):83-92.

**Open Access** This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

